shares in euroapi sa plummeted wednesday after the company said its net loss almost doubled in 2022 mainly due to oneoff impairments and delayed its midterm margin target by one year to 2026 the french manufacturer of active pharmaceutical ingredients said its net loss widened to eur150 million in 2022 compared with eur81 million in 2021 the loss includes eur288 million noncash impairments on its site in brindisi italy and a deferred tax asset impairment the company said sales were eur9766 million up from eur8928 million a year prior earnings before interest taxes depreciation and amortization fell to eur937 million compared with eur1028 million a year before which includes eur263 million in expenses associated with euroapis listing on euronext paris it said core ebitda rose 85 to eur120 million with a margin of 123 for 2023 the company expects sales to increase between 7 and 8 with a core ebitda margin of 1214 the company said it now expects core ebitda margin to exceed 20 in 2026 a year later than initially forecast net sales are expected to increase by an average of between 7 and 8 for the 20232026 period against prior expectations of 67 growth in the 20212025 period euroapi said